Therapy of Primary Liver Cancer

Overview

Journal Innovation (Camb)

Publisher Cell Press

Specialty Biomedical Engineering

Date 2020 Sep 11

PMID 32914142

Citations 40

Authors

Mei Feng

Yisheng Pan

Ruirui Kong

Shaokun Shu

Affiliations

Soon will be listed here.

Abstract

Primary liver cancer (PLC) is a fatal disease that affects millions of lives worldwide. PLC is the leading cause of cancer-related deaths and the incidence rate is predicted to rise in the coming decades. PLC can be categorized into three major histological subtypes: hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and combined HCC-ICC. These subtypes are distinct with respect to epidemiology, clinicopathological features, genetic alterations, and clinical managements, which are thoroughly summarized in this review. The state of treatment strategies for each subtype, including the currently approved drugs and the potential novel therapies, are also discussed.

Citing Articles

Microbiome interplays in the gut-liver axis: implications for liver cancer pathogenesis and therapeutic insights.

Wang X, Zhang B, Jiang R Front Cell Infect Microbiol. 2025; 15:1467197.

PMID: 39936163 PMC: 11810975. DOI: 10.3389/fcimb.2025.1467197.

Single-cell landscape of dynamic changes in CD8 T cells, CD4 T cells and exhausted T cells in hepatocellular carcinoma.

Liu R, Ye J, Wang J, Ma W, Qiu Z, Yu J Sci Rep. 2025; 15(1):4130.

PMID: 39900964 PMC: 11791069. DOI: 10.1038/s41598-025-88377-7.

Recent Trends in Liver Cancer: Epidemiology, Risk Factors, and Diagnostic Techniques.

Kale S, Karande G, Gudur A, Garud A, Patil M, Patil S Cureus. 2024; 16(10):e72239.

PMID: 39583507 PMC: 11584332. DOI: 10.7759/cureus.72239.

Utilization of Microfluidic Droplet-Based Methods in Diagnosis and Treatment Methods of Hepatocellular Carcinoma: A Review.

Zajanckauskaite A, Lingelbach M, Juozapaite D, Utkus A, Ruksnaityte G, Jonuskiene G Genes (Basel). 2024; 15(10).

PMID: 39457366 PMC: 11508129. DOI: 10.3390/genes15101242.

Hepatocyte-specific Smad4 deficiency inhibits hepatocarcinogenesis by promoting CXCL10/CXCR3-dependent CD8- T cell-mediated anti-tumor immunity.

Xin X, Li Z, Yan X, Liu T, Li Z, Chen Z Theranostics. 2024; 14(15):5853-5868.

PMID: 39346534 PMC: 11426237. DOI: 10.7150/thno.97276.

References

Kim G, Jeung H, Kim D, Kim J, Yoon S, Jung E . A case of combined hepatocellular-cholangiocarcinoma with favorable response to systemic chemotherapy. Cancer Res Treat. 2011; 42(4):235-8. PMC: 3021743. DOI: 10.4143/crt.2010.42.4.235. View

Cleary S, Jeck W, Zhao X, Chen K, Selitsky S, Savich G . Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology. 2013; 58(5):1693-702. PMC: 3830584. DOI: 10.1002/hep.26540. View

Desrichard A, Snyder A, Chan T . Cancer Neoantigens and Applications for Immunotherapy. Clin Cancer Res. 2015; 22(4):807-12. DOI: 10.1158/1078-0432.CCR-14-3175. View

Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M . Genomic spectra of biliary tract cancer. Nat Genet. 2015; 47(9):1003-10. DOI: 10.1038/ng.3375. View

Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View

Huang C, Hsieh F, Wang C, Chen L, Chang S, Tsai M . Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response. Eur J Cancer. 2018; 102:10-22. DOI: 10.1016/j.ejca.2018.07.010. View

Spratlin J, Cohen R, Eadens M, Gore L, Camidge D, Diab S . Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010; 28(5):780-7. PMC: 2834394. DOI: 10.1200/JCO.2009.23.7537. View

Chan-On W, Nairismagi M, Ong C, Lim W, Dima S, Pairojkul C . Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 2013; 45(12):1474-8. DOI: 10.1038/ng.2806. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

10.

Razumilava N, Gores G . Cholangiocarcinoma. Lancet. 2014; 383(9935):2168-79. PMC: 4069226. DOI: 10.1016/S0140-6736(13)61903-0. View

11.

Nagtegaal I, Odze R, Klimstra D, Paradis V, Rugge M, Schirmacher P . The 2019 WHO classification of tumours of the digestive system. Histopathology. 2019; 76(2):182-188. PMC: 7003895. DOI: 10.1111/his.13975. View

12.

Yakes F, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P . Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011; 10(12):2298-308. DOI: 10.1158/1535-7163.MCT-11-0264. View

13.

Sidaway P . MSI-H: a truly agnostic biomarker?. Nat Rev Clin Oncol. 2019; 17(2):68. DOI: 10.1038/s41571-019-0310-5. View

14.

Boehm L, Jayakrishnan T, Miura J, Zacharias A, Johnston F, Turaga K . Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol. 2014; 111(2):213-20. DOI: 10.1002/jso.23781. View

15.

Sasaki M, Sato Y, Nakanuma Y . Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance. Histopathology. 2016; 70(3):423-434. DOI: 10.1111/his.13084. View

16.

Yarchoan M, Johnson 3rd B, Lutz E, Laheru D, Jaffee E . Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer. 2017; 17(4):209-222. PMC: 5575801. DOI: 10.1038/nrc.2016.154. View

17.

Hyder O, Marsh J, Salem R, Petre E, Kalva S, Liapi E . Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol. 2013; 20(12):3779-86. DOI: 10.1245/s10434-013-3127-y. View

18.

Qin S, Bai Y, Lim H, Thongprasert S, Chao Y, Fan J . Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013; 31(28):3501-8. DOI: 10.1200/JCO.2012.44.5643. View

19.

Cercek A, Boerner T, Tan B, Chou J, Gonen M, Boucher T . Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2019; 6(1):60-67. PMC: 6824231. DOI: 10.1001/jamaoncol.2019.3718. View

20.

Krook M, Lenyo A, Wilberding M, Barker H, Dantuono M, Bailey K . Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma. Mol Cancer Ther. 2020; 19(3):847-857. PMC: 7359896. DOI: 10.1158/1535-7163.MCT-19-0631. View